As one could argue the effects that radiation displays in regard to HuR’s biological behavior, Tatarian et al. [73] utilized tumor samples from the international European Study Group of Pancreatic Cancer-3 trial, where patients with PDA received either gemcitabine or 5-FU adjuvant monotherapy in the absence of adjuvant radiation, to provide evidence of HuR’s role as a prognostic and predictive biomarker [73]. This evidence concerns the gene ELAVL1 and Patent ductus arteriosus.